
ICYMI: Daria Lemann Blumenthal, CEO of BELKIN Laser, Ltd., discusses the company's current initiative of developing an automated one-second laser therapy for glaucoma called direct selective laser trabeculoplasty (DSLT).

ICYMI: Daria Lemann Blumenthal, CEO of BELKIN Laser, Ltd., discusses the company's current initiative of developing an automated one-second laser therapy for glaucoma called direct selective laser trabeculoplasty (DSLT).

Patient expectations continue to push clinicians to look at optimal ways to arrive at the best IOLs.






















